SEPREHVEC - A TECHNOLOGY PLATFORM

SEPREHVIR is the first in a series of oncolytic immunotherapies engineered by VIRTTU that have significant therapeutic potential.

VIRTTU has also developed a proprietary platform (SEPREHVEC) which aims to provide additional therapeutic options and can rapidly generate novel oncolytic immunotherapies that are:

  • "targeted" specifically to tumour cells; and/or
  • "armed" with additional genes to enhance the destruction of tumour cells
  • multi-functional"targeted" and "armed" variants with enhanced cell killing and immuno-stimulatory activities.